Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DX9GT7
|
|||
| Drug Name |
Nofazinlimab
|
|||
| Synonyms |
EQ176; CS1003
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Liver cancer [ICD-11: 2C12; ICD-10: C22] | Phase 3 | [1] | |
| Company |
EQRx
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Programmed cell death protein 1 (PD-1) | Target Info | . | [2] |
| KEGG Pathway | Cell adhesion molecules (CAMs) | |||
| T cell receptor signaling pathway | ||||
| Reactome | PD-1 signaling | |||
| WikiPathways | T-Cell Receptor and Co-stimulatory Signaling | |||
| Costimulation by the CD28 family | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04194775) A Multi-Center, Double-Blind, Randomized, Phase III Study to Investigate the Efficacy and Safety of Nofazinlimab (CS1003) in Combination With Lenvatinib Compared to Placebo in Combination With Lenvatinib as First-Line Therapy in Subjects With Advanced Hepatocellular Carcinoma (HCC). U.S.National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of EQRx | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.